Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Jagsonpal Pharmaceuticals's
Operating Income
for the
three
months ended in Jun. 2026 was ₹151 Mil. Jagsonpal Pharmaceuticals's Interest Expense for the
three
months ended in Jun. 2026 was ₹-3 Mil.
Jagsonpal Pharmaceuticals's interest coverage for the quarter that ended in Jun. 2026 was 60.15.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Jagsonpal Pharmaceuticals Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Jagsonpal Pharmaceuticals's Interest Coverage or its related term are showing as below:
NSE:JAGSNPHARM'
s Interest Coverage Range Over the Past 10 Years
Min: 1.67 Med: 43.94 Max: 123.49
Current: 50.6
NSE:JAGSNPHARM's Interest Coverage is ranked better than 70.82% of 682
companies
in the Drug Manufacturers industry
Industry Median: 12.82
vs NSE:JAGSNPHARM: 50.60
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Jagsonpal Pharmaceuticals Interest Coverage Related Terms
Jagsonpal Pharmaceuticals Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:JAGSNPHARM vs ZTS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jagsonpal Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Jagsonpal Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) has a Interest Coverage of 60.15 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jagsonpal Pharmaceuticals and its competitors. This is 37% above median its historical median of 43.94. Over the past decade, Jagsonpal Pharmaceuticals' Interest Coverage has ranged from 1.67 to 123.49. According to the industry distribution chart, Jagsonpal Pharmaceuticals ranks #199 out of 682 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Jagsonpal Pharmaceuticals' Interest Coverage too high?
Jagsonpal Pharmaceuticals' current Interest Coverage of 60.15 is 37% above median its 10-year median of 43.94. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 123.49. The Drug Manufacturers industry median Interest Coverage is 12.82. Jagsonpal Pharmaceuticals' value of 60.15 is 369.2% above this industry median. Based on the distribution chart, Jagsonpal Pharmaceuticals ranks #199 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jagsonpal Pharmaceuticals ranks #199 out of 682 companies for Interest Coverage. This puts Jagsonpal Pharmaceuticals in the upper half of its industry. The industry median Interest Coverage is 12.82. Jagsonpal Pharmaceuticals' value of 60.15 is 369.2% above this benchmark. Historically, Jagsonpal Pharmaceuticals' own Interest Coverage has ranged from 1.67 to 123.49 over the past decade. While the company's 10-year median is 43.94 vs. the industry median of 12.82, Jagsonpal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.82, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jagsonpal Pharmaceuticals's current Interest Coverage of 60.15 is 369.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jagsonpal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jagsonpal Pharmaceuticals's current Interest Coverage is 60.15, which is 37% above median its own 10-year median of 43.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹219.46, compared to a current price of ₹226.55 — trading 3.2% above its estimated fair value. The current Interest Coverage is 60.15, which is 37% above median its 10-year median of 43.94 and 369.2% above the Drug Manufacturers industry median of 12.82. Jagsonpal Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM), the current Interest Coverage is 60.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹226.55 is trading 3.2% above its estimated GF Value™ of ₹219.46.
GuruFocus considers Jagsonpal Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:JAGSNPHARM:
Interest Coverage: 60.15 (37% above median its 10-year median of 43.94)
GF Value™: ₹219.46 vs. price of ₹226.55 (3.2% above fair value)
Industry Position: 369.2% above the Drug Manufacturers median (#199 of 682)
No single metric tells the full story. See the NSE:JAGSNPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
81GF Score
Get the complete analysis for NSE:JAGSNPHARM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JAGSNPHARM has been successfully added to your 
